Irreversible erbB family blocker may be beneficial to the patients with EGFR-TKI resistant NSCLC and trastuzumab resistant HER2-positive metastatic breast cancer (MBC) [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.